Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.34 |
| ▸ | P2RY1 | P47900 | 3/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16132302 | 0.84 | OPRL1 (0.41) | OPRL1P2RY1TRPV1RBP4CA2 | |
| SCHEMBL16132340 | 0.81 | OPRL1 (0.40) | OPRL1P2RY1TRPV1RBP4CA2 | |
| SCHEMBL31438527 | 0.73 | KDM4E (0.34) | PDE1APDE1BPDE1C | |
| SCHEMBL25190850 | 0.73 | KDM4E (0.34) | PDE1APDE1BPDE1C | |
| SCHEMBL31610808 | 0.72 | CHRNA7 (0.44) | OPRL1TRPV1CA2NISCHTSHR | |
| SCHEMBL27270827 | 0.72 | CHRNA7 (0.44) | OPRL1TRPV1CA2NISCHTSHR | |
| SCHEMBL25725449 | 0.71 | OPRL1 (0.31) | OPRL1 | |
| SCHEMBL1116651 | 0.70 | PARP1 (0.46) | OPRL1ALDH1A1TDP1 | |
| SCHEMBL25864362 | 0.68 | — | — | |
| SCHEMBL9768975 | 0.67 | KDM4E (0.37) | OPRL1ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | IDH1 449/4885OPRL1 4103/4885P2RY1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.